The Food and Drug Administration last night said it determined the shortage of tirzepatide injection, a glucagon-like peptide medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand, the agency noted. The FDA confirmed with Eli Lilly that its stated product availability and manufacturing capacity can meet the present and projected national demand. “Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies,” the FDA added. The agency reminded “compounders of the legal restrictions on making copies of FDA-approved drugs.” Compounded drugs “are not approved by FDA. FDA-approved drugs go through FDA’s rigorous review for safety, effectiveness, and quality as part of the premarket approval process,” the agency added. Shares of compounded drug maker Hims & Hers (HIMS) are down 7% to $17.56 in premarket trading after the FDA said Eli Lill’s weight-loss drug shortage is over.